Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 583

1.

Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Khan MK, Nasti TH, Buchwald ZS, Weichselbaum RR, Kron SJ.

Cancer J. 2019 Mar/Apr;25(2):106-115. doi: 10.1097/PPO.0000000000000369.

PMID:
30896532
2.

Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells.

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, Bissonnette MB, Shen B, Weichselbaum RR, Xu MM, He C.

Nature. 2019 Feb;566(7743):270-274. doi: 10.1038/s41586-019-0916-x. Epub 2019 Feb 6.

PMID:
30728504
3.

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.

Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, Koshy M.

Radiat Oncol. 2019 Jan 28;14(1):18. doi: 10.1186/s13014-019-1222-3.

4.

DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs.

Oshima G, Poli EC, Bolt MJ, Chlenski A, Forde M, Jutzy JMS, Biyani N, Posner MC, Pitroda SP, Weichselbaum RR, Khodarev NN.

Cancer Res. 2019 Feb 1;79(3):650-662. doi: 10.1158/0008-5472.CAN-18-0692. Epub 2018 Dec 11.

PMID:
30538122
5.

Oligometastatic prostate cancer: Reality or figment of imagination?

Foster CC, Weichselbaum RR, Pitroda SP.

Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860. Epub 2018 Dec 6. Review.

PMID:
30521067
6.

STING promotes homeostasis via regulation of cell proliferation and chromosomal stability.

Ranoa DRE, Widau RC, Mallon S, Parekh AD, Nicolae CM, Huang X, Bolt MJ, Arina A, Parry R, Kron SJ, Moldovan GL, Khodarev NN, Weichselbaum RR.

Cancer Res. 2018 Nov 27. pii: canres.1972.2018. doi: 10.1158/0008-5472.CAN-18-1972. [Epub ahead of print]

PMID:
30482772
7.

Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR.

Nat Commun. 2018 Nov 13;9(1):4827. doi: 10.1038/s41467-018-07303-w.

8.

Oxygen-Guided Radiation Therapy.

Epel B, Maggio MC, Barth ED, Miller RC, Pelizzari CA, Krzykawska-Serda M, Sundramoorthy SV, Aydogan B, Weichselbaum RR, Tormyshev VM, Halpern HJ.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):977-984. doi: 10.1016/j.ijrobp.2018.10.041. Epub 2018 Nov 8.

PMID:
30414912
9.

The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment.

Weichselbaum RR.

J Clin Oncol. 2018 Sep 27:JCO1800847. doi: 10.1200/JCO.18.00847. [Epub ahead of print]

PMID:
30260759
10.

Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy.

Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, Arina A, Weichselbaum RR, Fu YX.

Immunity. 2018 Sep 18;49(3):490-503.e4. doi: 10.1016/j.immuni.2018.07.008. Epub 2018 Aug 28.

PMID:
30170810
11.

BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.

Wu L, Bernal GM, Cahill KE, Pytel P, Fitzpatrick CA, Mashek H, Weichselbaum RR, Yamini B.

Sci Transl Med. 2018 Jul 4;10(448). pii: eaar2238. doi: 10.1126/scitranslmed.aar2238.

PMID:
29973405
12.

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy.

Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W.

Nat Commun. 2018 Jun 15;9(1):2351. doi: 10.1038/s41467-018-04703-w.

13.

Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR.

Nat Commun. 2018 May 4;9(1):1793. doi: 10.1038/s41467-018-04278-6. Erratum in: Nat Commun. 2018 Nov 13;9(1):4827.

14.

ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response.

Murley JS, Arbiser JL, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2018 Aug 1;123:39-52. doi: 10.1016/j.freeradbiomed.2018.04.547. Epub 2018 Apr 13.

PMID:
29660403
15.

Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.

Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK.

PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149. eCollection 2018.

16.

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.

Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN.

Mol Cancer Ther. 2018 Apr;17(4):732-739. doi: 10.1158/1535-7163.MCT-17-0667. Epub 2018 Feb 21.

PMID:
29467274
17.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

PMID:
29437535
18.

Host STING-dependent MDSC mobilization drives extrinsic radiation resistance.

Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, Zheng W, Mauceri H, Mack M, Xu M, Fu YX, Weichselbaum RR.

Nat Commun. 2017 Nov 23;8(1):1736. doi: 10.1038/s41467-017-01566-5.

19.

Retuning the Radio in Radiobiology.

Chmura SJ, Connell PP, Weichselbaum RR.

J Natl Cancer Inst. 2018 Apr 1;110(4):325-326. doi: 10.1093/jnci/djx234. No abstract available.

PMID:
29126281
20.

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.

Patel P, Oh AL, Koshy M, Sweiss K, Saraf SL, Quigley JG, Khan I, Mahmud N, Hacker E, Ozer H, Peace DJ, Weichselbaum RR, Aydogan B, Rondelli D.

Leuk Lymphoma. 2018 Jul;59(7):1666-1671. doi: 10.1080/10428194.2017.1390231. Epub 2017 Oct 25.

PMID:
29065747
21.

HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation.

Efimova EV, Ricco N, Labay E, Mauceri HJ, Flor AC, Ramamurthy A, Sutton HG, Weichselbaum RR, Kron SJ.

Mol Cancer Ther. 2018 Feb;17(2):407-418. doi: 10.1158/1535-7163.MCT-17-0288. Epub 2017 Oct 13.

22.

Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers.

Spiotto MT, Jefferson GD, Wenig B, Markiewicz MR, Weichselbaum RR, Koshy M.

Head Neck. 2017 Dec;39(12):2537-2548. doi: 10.1002/hed.24932. Epub 2017 Sep 27.

PMID:
28960621
23.

Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.

Koshy M, Sher DJ, Spiotto M, Husain Z, Engelhard H, Slavin K, Nicholas MK, Weichselbaum RR, Rusthoven C.

J Neurooncol. 2017 Dec;135(3):529-534. doi: 10.1007/s11060-017-2598-2. Epub 2017 Aug 23.

PMID:
28836140
24.

TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.

Murley JS, Miller RC, Weichselbaum RR, Grdina DJ.

Radiat Res. 2017 Nov;188(5):579-590. doi: 10.1667/RR14831.1. Epub 2017 Aug 16.

25.

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.

Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, Chen X, Li XD, Deng L, Chen ZJ, Weichselbaum RR, Fu YX.

Immunity. 2017 Aug 15;47(2):363-373.e5. doi: 10.1016/j.immuni.2017.07.016. Epub 2017 Aug 8.

26.

Rhythmic radiotherapy beats down TGF-β.

Chmura SJ, Weichselbaum RR.

Cell Cycle. 2017 Aug 3;16(15):1391. doi: 10.1080/15384101.2017.1337970. Epub 2017 Jul 19. No abstract available.

PMID:
28727497
27.

Rhythmic radiotherapy beats down TGF-β.

Chmura SJ, Weichselbaum RR.

Cell Cycle. 2017 Aug 3;16(15):1391. doi: 10.1080/15384101.2017.1337970. Epub 2017 Jul 19. No abstract available.

PMID:
28723240
28.

Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation.

Zhang Y, Kim TJ, Wroblewska JA, Tesic V, Upadhyay V, Weichselbaum RR, Tumanov AV, Tang H, Guo X, Tang H, Fu YX.

Cell Mol Immunol. 2018 Jul;15(7):697-709. doi: 10.1038/cmi.2017.25. Epub 2017 Jun 5.

PMID:
28579615
29.

In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases.

Oshima G, Guo N, He C, Stack ME, Poon C, Uppal A, Wightman SC, Parekh A, Skowron KB, Posner MC, Lin W, Khodarev NN, Weichselbaum RR.

Mol Ther. 2017 Jul 5;25(7):1588-1595. doi: 10.1016/j.ymthe.2017.04.005. Epub 2017 Apr 28.

30.

Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis.

Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M.

JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699. doi: 10.1001/jamaoto.2017.0012.

31.

Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.

Pitroda SP, Bao R, Andrade J, Weichselbaum RR, Connell PP.

Clin Cancer Res. 2017 Aug 1;23(15):4493-4500. doi: 10.1158/1078-0432.CCR-16-2845. Epub 2017 Mar 24.

32.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME.

Cell Rep. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037.

33.

Radiotherapy and immunotherapy: a beneficial liaison?

Weichselbaum RR, Liang H, Deng L, Fu YX.

Nat Rev Clin Oncol. 2017 Jun;14(6):365-379. doi: 10.1038/nrclinonc.2016.211. Epub 2017 Jan 17. Review.

PMID:
28094262
34.

Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Arina A, Karrison T, Galka E, Schreiber K, Weichselbaum RR, Schreiber H.

Cancer Immunol Res. 2017 Feb;5(2):127-136. doi: 10.1158/2326-6066.CIR-16-0293. Epub 2017 Jan 11.

35.

The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Spiotto M, Fu YX, Weichselbaum RR.

Sci Immunol. 2016 Sep;1(3). pii: EAAG1266. doi: 10.1126/sciimmunol.aag1266. Epub 2016 Sep 30.

36.

Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.

Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):450-461. doi: 10.1016/j.ijrobp.2016.10.042. Epub 2016 Nov 8.

37.

Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.

Duan X, Chan C, Guo N, Han W, Weichselbaum RR, Lin W.

J Am Chem Soc. 2016 Dec 28;138(51):16686-16695. doi: 10.1021/jacs.6b09538. Epub 2016 Dec 15.

38.

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones.

Oshima G, Stack ME, Wightman SC, Bryan D, Poli E, Xue L, Skowron KB, Uppal A, Pitroda SP, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN.

J Vis Exp. 2016 Nov 30;(117). doi: 10.3791/54657.

39.

Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers.

Skowron KB, Pitroda SP, Namm JP, Balogun O, Beckett MA, Zenner ML, Fayanju O, Huang X, Fernandez C, Zheng W, Qiao G, Chin R, Kron SJ, Khodarev NN, Posner MC, Steinberg GD, Weichselbaum RR.

Sci Rep. 2016 Oct 24;6:35854. doi: 10.1038/srep35854.

40.

Very low doses of ionizing radiation and redox associated modifiers affect survivin-associated changes in radiation sensitivity.

Miller RC, Murley JS, Rademaker AW, Woloschak GE, Li JJ, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2016 Oct;99:110-119. doi: 10.1016/j.freeradbiomed.2016.07.009. Epub 2016 Jul 15.

PMID:
27427516
41.

Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy.

Lu K, He C, Guo N, Chan C, Ni K, Weichselbaum RR, Lin W.

J Am Chem Soc. 2016 Sep 28;138(38):12502-10. doi: 10.1021/jacs.6b06663. Epub 2016 Sep 14.

42.

Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment.

Appelbe OK, Zhang Q, Pelizzari CA, Weichselbaum RR, Kron SJ.

Mol Pharm. 2016 Oct 3;13(10):3457-3467. Epub 2016 Sep 1.

43.

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.

He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, Lin W.

Nat Commun. 2016 Aug 17;7:12499. doi: 10.1038/ncomms12499.

44.

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy.

Michelle Xu M, Pu Y, Weichselbaum RR, Fu YX.

Oncogene. 2017 Feb 2;36(5):585-592. doi: 10.1038/onc.2016.231. Epub 2016 Jul 18. Review.

45.

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.

Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR.

Oncotarget. 2016 Jul 12;7(28):43039-43051. doi: 10.18632/oncotarget.9915.

46.

Tumor-associated fibroblasts predominantly come from local and not circulating precursors.

Arina A, Idel C, Hyjek EM, Alegre ML, Wang Y, Bindokas VP, Weichselbaum RR, Schreiber H.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7551-6. doi: 10.1073/pnas.1600363113. Epub 2016 Jun 17.

47.

Nonmuscle myosin light chain kinase activity modulates radiation-induced lung injury.

Wang T, Mathew B, Wu X, Shimizu Y, Rizzo AN, Dudek SM, Weichselbaum RR, Jacobson JR, Hecker L, Garcia JG.

Pulm Circ. 2016 Jun;6(2):234-9. doi: 10.1086/686491.

48.

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.

Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R.

Oncotarget. 2017 Mar 21;8(12):18726-18734. doi: 10.18632/oncotarget.9640.

49.

Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).

Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ.

Cancer. 2016 Jul 15;122(14):2242-50. doi: 10.1002/cncr.30058. Epub 2016 May 20.

50.

In Reply to Zaghloul.

Liauw SL, Reddy AV, Weichselbaum RR, Smith ND, Steinberg GD.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):855. doi: 10.1016/j.ijrobp.2016.01.050. No abstract available.

PMID:
27131088

Supplemental Content

Loading ...
Support Center